Economic evaluation of low-dose rivaroxaban adding on aspirin for the patients with stable cardiovascular disease from the perspective of Taiwan national payers

8 November 2019 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Poster Session Saturday 1 Health Economics ESC Premium Access ESC Asia with APSC & AFC

ESC 365 is supported by

ESC 365 is supported by